



Cybin Announces Conditional Listing Approval from NYSE American

7.21.21

**TORONTO,
CANADA**

–

July
21,
2021

–

Cybin
Inc.
(NEO:CYBN)
(OTCQB:CLXPF)
("Cybin")
or



[Our Work](#)

[Investors](#)

[About Us](#)

a
biotechnology
company
focused
on
progressing
psychedelic
therapeutics,
today
announced
that
it
has
received
conditional
listing
approval
from
the
NYSE
American
LLC
stock
exchange
(the



[Our Work](#)

[Investors](#)

[About Us](#)

Doug
Drysdale,
Cybin’s
CEO,
added,
“Conditional
listing
approval
on
the
NYSE
American
is
an
important
milestone
in
Cybin’s
growth
journey.
We
expect
expanded
access



Our Work

Investors

About Us

to
further
fuel
our
mission
to
develop
revolutionary
psychedelic
therapeutics
for
patients
suffering
from
mental
health
conditions.”

Any
listing
remains
subject
to
the
approval



[Our Work](#)

[Investors](#)

[About Us](#)

NYSE
American
and
the
satisfaction
of
all
applicable
regulatory
requirements.
No
assurance
can
be
given
that
an
application
will
be
approved.
The
Company
plans
to



[Our Work](#)

[Investors](#)

[About Us](#)

current
listing
on
the
NEO
Exchange.
The
Company
has
reserved
the
ticker
CYBN
on
the
NYSE
American.

About

Cybin

Cybin

is

a

leading



[Our Work](#)

[Investors](#)

[About Us](#)

focused
on
progressing
psychedelic
therapeutics
by
utilizing
proprietary
drug
discovery
platforms,
innovative
drug
delivery
systems,
novel
formulation
approaches
and
treatment
regimens
for
psychiatric
disorders.



[Our Work](#)

[Investors](#)

[About Us](#)

----- ,

**Notes
and
Forward-
Looking
Statements**

Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature.



Our Work

Investors

About Us

statements
are
not
based
on
historical
facts,
but
rather
on
current
expectations
and
projections
about
future
events
and
are
therefore
subject
to
risks
and
uncertainties



Our Work

Investors

About Us

cause
actual
results
to
differ
materially
from
the
future
results
expressed
or
implied
by
the
forward-
looking
statements.
These
statements
generally
can
be
identified
by



Our Work

Investors

About Us

of
forward-
looking
words
such
as
“may”,
“should”,
“could”,
“intend”,
“estimate”,
“plan”,
“anticipate”,
“expect”,
“believe”
or
“continue”,
or
the
negative
thereof
or
similar
variations.
Forward-



[Our Work](#)

[Investors](#)

[About Us](#)

in
this
news
release
include
statements
regarding
the
Company's
potential
listing
on
NYSE
American.
There
are
numerous
risks
and
uncertainties
that
could
cause
actual
results



[Our Work](#)

[Investors](#)

[About Us](#)

plans
and
objectives
to
differ
materially
from
those
expressed
in
the
forward-
looking
information.

Actual
results
and
future
events
could
differ
materially
from
those
anticipated



[Our Work](#)

[Investors](#)

[About Us](#)

information.

These

and

all

subsequent

written

and

oral

forward-

looking

information

are

based

on

estimates

and

opinions

of

management

on

the

dates

they

are

made

[Our Work](#)[Investors](#)[About Us](#)

expressly
qualified
in
their
entirety
by
this
notice.
Except
as
required
by
law,
the
Company
does
not
intend
to
update
these
forward-
looking
statements.



[Our Work](#)

[Investors](#)

[About Us](#)

no
medical,
treatment
or
health
benefit
claims
about
Cybin's
proposed
products.
The
U.S.
Food
and
Drug
Administration,
Health
Canada
or
other
similar
regulatory
authorities
have



[Our Work](#)

[Investors](#)

[About Us](#)

claims
regarding
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or
nutraceutical
products.

The
efficacy
of
such
products
have
not
been
confirmed
by
approved



[Our Work](#)

[Investors](#)

[About Us](#)

is
no
assurance
that
the
use
of
psilocybin,
psychedelic
tryptamine,
tryptamine
derivatives
or
other
psychedelic
compounds
or
nutraceuticals
can
diagnose,
treat,
cure
or
prevent
any



[Our Work](#)

[Investors](#)

[About Us](#)

condition.

Vigorous

scientific

research

and

clinical

trials

are

needed.

Cybin

has

not

conducted

clinical

trials

for

the

use

of

its

proposed

products.

Any

references

to



[Our Work](#)

[Investors](#)

[About Us](#)

efficacy
and
safety
of
potential
products
do
not
imply
that
Cybin
verified
such
in
clinical
trials
or
that
Cybin
will
complete
such
trials.
If
Cybin



[Our Work](#)

[Investors](#)

[About Us](#)

the
approvals
or
research
necessary
to
commercialize
its
business,
it
may
have
a
material
adverse
effect
on
Cybin's
performance
and
operations.

*The
NEO
Exchange*



Our Work

Investors

About Us

*approved
nor
disapproved
the
contents
of
this
news
release
and
is
not
responsible
for
the
adequacy
and
accuracy
of
the
contents
herein.*

Investor

Contacts:



Our Work

Investors

About Us

Eckstein

KCSA

Strategic

Communications

Cybin@kcsa.com

Lisa

M.

Wilson

In-

Site

Communications,

Inc.

lwilson@insitecony.com

Media

Contacts:

John

Kanakis

Cybin

Inc.

John@cybin.com



Our Work

Investors

About Us



5600-100 King St W, Toronto ON
 M5X 1C9
 Investor Contact: ir@cybin.com
 General Contact:
info@cybin.com

Our Work

[Development Pipeline](#)
[The Science](#)
[Cybin x Kernel](#)

Investors

[Press Releases](#)
[Financials](#)
[Corporate Governance](#)
[Downloads](#)

About Us

[Mission](#)
[Team](#)
[News](#)
[Join Us](#)
[Contact](#)



Copyright Cybin Corp. © 2021 . All rights reserved.

[Privacy Policy](#)